

Helicobacter Pylori Eradication

Submission date 23/11/2014	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 10/12/2014	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 10/05/2021	Condition category Infections and Infestations	☐ Individual participant data

Plain English summary of protocol

Background and study aims

Helicobacter pylori (HP) is a bacteria that can infect the stomach lining and duodenum (first part of the intestine). Once infected, unless treated, a person is infected for life. Most people have no symptoms (asymptomatic). However, it can cause ulcers, indigestion, nausea and vomiting, extreme tiredness (fatigue) and tarry stools. Over time,, it can also increase the risk of stomach cancer. Patients with symptoms can be offered eradication therapy, which consists of a combination of antibiotics. HP eradication is still a problem, however, as desired levels of treatment have not been achieved yet. Here, we want to find out whether the success rate of HP eradication is lower in a country where the rate of HP infection is high and is there any benefit to treating asymptomatic HP-positive (infected) partners at the same time as symptomatic HP-positive patients.

Who can participate?

Adult symptomatic HP-positive patients and their asymptomatic HP-positive partners.

What does the study involve?

The patients are randomized into two groups. Those in group 1 are treated for HP infection and so are their partners. Those in group 2 are also treated but their partners are not. The treated offered to all participants is a combination therapy of levofloxacin 500 mg daily, amoxicillin 1g b. i.d and lansoprazole 30 mg b.i.d (LAL) for ten days. The presence of HP bacteria is then tested for by a stool antigen test six weeks later.

What are the possible benefits and risks of participating?

Not provided at time of registration.

Where is the study run from?

Recep Tayyip Erdoğan (RTE) University, Gastroenterology Polyclinic (Turkey)

When is the study starting and how long is it expected to run for?

January 2013 to November 2014

Who is funding the study?

Recep Tayyip Erdoğan (RTE) University, Gastroenterology Polyclinic (Turkey)

Who is the main contact?
Dr Halil Rakici
halilrakici59@hotmail.com

Contact information

Type(s)
Scientific

Contact name
Dr Halil Rakici

Contact details
Recep Tayyip Erdogan University
Rize
Türkiye
53100
+905326869760
halilrakici59@hotmail.com

Additional identifiers

Protocol serial number
210247

Study information

Scientific Title
Is There Any Advantage of Treating Partners in Helicobacter Pylori Eradication?

Study objectives
Effects of partners and reinfection on H.pylori eradication were studied.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Ethics Committee RTE University , 17/10/2014, ref. 2014/132

Primary study design
Interventional

Study design
Single-centre, prospective, controlled.

Study type(s)
Treatment

Health condition(s) or problem(s) studied

Helicobacter pylori (HP) infection

Interventions

The participants were randomised into two groups:

Group 1: HP-positive patients and HP-positive partners were treated with levofloxacin 500 mg daily, amoxicillin 1g b.i.d and lansoprazole 30 mg b.i.d (LAL) for ten days.

Group 2: Only the HP-positive patients were treated with levofloxacin 500 mg daily, amoxicillin 1g b.i.d and lansoprazole 30 mg b.i.d (LAL) for ten days.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

1. Levofloxacin 2. Amoxicillin 3. Lansoprazole

Primary outcome(s)

Eradication success rate

Key secondary outcome(s)

Re-infection rate between partners

Completion date

30/11/2014

Eligibility

Key inclusion criteria

Helicobacter pylori positive patients and their partners

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Total final enrolment

206

Key exclusion criteria

People who are Helicobacter pylori negative

Date of first enrolment

13/01/2013

Date of final enrolment

31/10/2014

Locations

Countries of recruitment

Türkiye

Study participating centre

Recep Tayyip Erdoğan (RTE) University, Gastroenterology Polyclinic

Rize

Türkiye

53100

Sponsor information

Organisation

Recep Tayyip Erdogan University

ROR

<https://ror.org/0468j1635>

Funder(s)

Funder type

University/education

Funder Name

Recep Tayyip Erdogan University (Turkey)

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		01/01/2015	10/05/2021	Yes	No